Patents by Inventor John P. Yardley
John P. Yardley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090326075Abstract: This invention provides pharmaceutically active enantiomers of the venlafaxine metabolite O-Desmethyl venlafaxine, R(?)-4-[2-(Dimethylamino-1-(1-hydroxycyclo-hexyl)ethyl]phenol or R(?)1-[2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclo-hexanol, and S(+)-1-[2-(Dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol or S(+)-4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol, or one or more pharmaceutically acceptable salts or salt hydrates thereof, as well as pharmaceutical compositions utilizing these enantiomers and methods of using the enantiomers to treat, inhibit or control central nervous system disorders.Type: ApplicationFiled: September 4, 2009Publication date: December 31, 2009Applicant: WyethInventors: John P. Yardley, Andrew A. Asselin
-
Patent number: 7291646Abstract: This invention provides O-?-acyloxyalkyl ethers of the venlafaxine metabolite 4-[2-(Dimehtylamino-1-(1-hydroxycyclohexyl)ethyl]phenol, represented by Formula (I): wherein the variables R1 and R2 are defined herein, and where the configuration at the steriogenic center (*) may be R, S, or RS (the racemate).Type: GrantFiled: October 24, 2003Date of Patent: November 6, 2007Assignee: WyethInventors: John P. Yardley, Magid A. Abou-Gharbia, John W. Ullrich
-
Patent number: 6831084Abstract: This invention provides compounds and methods using them to provide neuroprotection and prevent or limit processes of neurodegeneration in mammals, including Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, AIDS dementia, retinal disease, diabetic peripheral neuropathy, multiple sclerosis, stroke, acute thromboembolic stroke, focal ischemia, global ischemia, transient ischemic attack, ischemia resulting from surgery, head trauma, spinal trauma, hypoxia, fetal hypoxia, and neuroprotection, the compounds having the structure: wherein X is —CH2— or a bond; Y is —(CH2)m— or —(CH2)—O—(CH2)—; m 0 or 1; n is 0 or 1; R1 and R2 are independently selected from optionally substituted aryl or heteroaryl; the optical isomers and the pharmaceutically acceptable salts thereof.Type: GrantFiled: November 6, 2000Date of Patent: December 14, 2004Assignee: WyethInventors: Wayne E. Childers, Jr., Horace Fletcher, III, Magid A. Abou-Gharbia, John P. Yardley
-
Patent number: 6828324Abstract: This invention provides compounds and methods using them to provide neuroprotection and prevent or limit processes of neurodegeneration in mammals, including Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, AIDS dementia, retinal disease, diabetic peripheral neuropathy, multiple sclerosis, stroke, acute thromboembolic stroke, focal ischemia, global ischemia, transient ischemic attack, ischemia resulting from surgery, head trauma, spinal trauma, hypoxia, fetal hypoxia, and neuroprotection. The compounds having the structure: wherein X is —CH2— or a bond; Y is —(CH2)m— or —(CH2)—O—(CH2)—; m 0 or 1; n is 0 or 1; R1 and R2 are independently selected from optionally substituted aryl or heteroaryl; the optical isomers and the pharmaceutically acceptable salts thereof.Type: GrantFiled: February 20, 2004Date of Patent: December 7, 2004Assignee: WyethInventors: Wayne E. Childers, Jr., Horace Fletcher, III, Magid A. Abou-Gharbia, John P. Yardley
-
Publication number: 20040180966Abstract: The present invention provides enantiomers of N-Desmethyl venlafaxine, as well as their use in pharmaceutical compositions and medically useful treatments, particularly including central nervous system uses.Type: ApplicationFiled: March 29, 2004Publication date: September 16, 2004Applicant: WyethInventors: John P. Yardley, Andre A. Asselin
-
Publication number: 20040176468Abstract: This invention provides pharmaceutically active enantiomers of the venlafaxine metabolite O-Desmethyl venlafaxine, R(−)-4-[2-(Dimethylamino-i-(1-hydroxycyclo-hexyl)ethyl]phenol or R(−)1-[2-(dimethylarinno)-1-(4-hydroxyphenyl)ethyl]cyclo-hexanol, and S(+)-1-[2-(Dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol or S(+)-4-[2-(Dimethylaamino)-1-(1-hydroxycyclohexyl)ethyl]phenol, or one or more pharmaceutically acceptable salts or salt hydrates thereof, as well as pharmaceutical compositions utilizing these enantiomers and methods of using the enantiomers to treat, inhibit or control central nervous system disorders.Type: ApplicationFiled: March 12, 2004Publication date: September 9, 2004Applicant: WyethInventors: John P. Yardley, Andre A. Asselin
-
Publication number: 20040162430Abstract: This invention provides compounds and methods using them to provide neuroprotection and prevent or limit processes of neurodegeneration in mammals, including Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, AIDS dementia, retinal disease, diabetic peripheral neuropathy, multiple sclerosis, stroke, acute thromboembolic stroke, focal ischemia, global ischemia, transient ischemic attack, ischemia resulting from surgery, head trauma, spinal trauma, hypoxia, fetal hypoxia, and neuroprotection.Type: ApplicationFiled: February 20, 2004Publication date: August 19, 2004Applicant: WyethInventors: Wayne E. Childers, Horace Fletcher, Magid A. Abou-Gharbia, John P. Yardley
-
Publication number: 20040147601Abstract: This invention provides O-&agr;-acyloxyalkyl ethers of the venlafaxine metabolite 4-[2-(Dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol, represented by Formula (I): 1Type: ApplicationFiled: October 24, 2003Publication date: July 29, 2004Applicant: WyethInventors: John P. Yardley, Magid A. Abou-Gharbia, John W. Ullrich
-
Publication number: 20030203972Abstract: The present invention provides enantiomers of N-Desmethyl venlafaxine, as well as their use in pharmaceutical compositions and medically useful treatments, particularly including central nervous system uses.Type: ApplicationFiled: April 21, 2003Publication date: October 30, 2003Applicant: WyethInventors: John P. Yardley, Andre A. Asselin
-
Publication number: 20030158253Abstract: This invention provides O-&agr;-acyloxyalkyl ethers of the venlafaxine metabolite 4-[2-(Dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol, represented by Formula (I): 1Type: ApplicationFiled: December 10, 2002Publication date: August 21, 2003Applicant: WyethInventors: John P. Yardley, Magid A. Abou-Gharbia, John W. Ullrich
-
Publication number: 20030149112Abstract: This invention provides pharmaceutically active enantiomers of the venlafaxine metabolite O-Desmethyl venlafaxine, R(−)-4-[2-(Dimethylamino-1-(1-hydroxycyclo-hexyl)ethyl]phenol or R(−)1-[2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclo-hexanol, and S(+)-1-[2-(Dimethylamino)-1-(4-hydroxycyclohexyl)ethyl]cyclohexanol or S(+)-4-[2-(Dimethylamino)-1-(1-hydroxcyclohexyl)ethyl]phenol,or one one or more pharmaceutically acceptable salts or salt hydrates thereof, as well as pharmaceutical compositions utilizing these enantiomers and methods of using the enantiomers to treat, inhibit or control central nervous system disorders.Type: ApplicationFiled: February 24, 2003Publication date: August 7, 2003Applicant: WyethInventors: John P. Yardley, Andre A. Asselin
-
Patent number: 6503942Abstract: This invention provides O-&agr;-acyloxyalkyl ethers of the venlafaxine metabolite 4-[2-(Dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol, represented by Formula (I): wherein: the configuration at the steriogenic center (*) may be R, S, or RS (the racemate); R1 is selected from C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, or the moiety: R2 is selected from H, or C1-C6 alkyl; or, R1 and R2 may be concatenated such that form a moiety having formula (b): R3 is selected from H or C1-C6 alkyl; and R4 and R5 are independently selected from H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 thioalkoxy, —CN, —OH, —CF3, —OCF3, halogen, —NH2, —NO2, or mono or dialkylamino wherein each alkyl group has 1 to 6 carbon atoms, or pharmaceutically acceptable salts or hydrates thereof, R, S, or RS forms thereof; as well as pharmaceutical compositions and methods treating central nervous system disoType: GrantFiled: November 21, 2001Date of Patent: January 7, 2003Assignee: WyethInventors: John P. Yardley, Magid A. Abou-Gharbia, John W. Ullrich
-
Publication number: 20020165284Abstract: The present invention provides enantiomers of N-Desmethyl venlafaxine, as well as their use in pharmaceutical compositions and medically useful treatments, particularly including central nervous system uses.Type: ApplicationFiled: July 3, 2002Publication date: November 7, 2002Applicant: WyethInventors: John P. Yardley, Andre A. Asselin
-
Publication number: 20020161055Abstract: This invention provides pharmaceutically active enantiomers of the venlafaxine metabolite O-Desmethyl venlafaxine, R(−)-4-[2-(Dimethylamino-1-(1-hydroxycyclo-hexyl)ethyl]phenol or R(−)1-[2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclo-hexanol, and S(+)-1-[2-(Dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol or S(+)-4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol, or one or more pharmaceutically acceptable salts or salt hydrates thereof, as well as pharmaceutical compositions utilizing these enantiomers and methods of using the enantiomers to treat, inhibit or control central nervous system disorders.Type: ApplicationFiled: May 23, 2002Publication date: October 31, 2002Applicant: Wyeth (formerly known as American Home Products Corporation)Inventors: John P. Yardley, Andre A. Asselin
-
Publication number: 20020037922Abstract: This invention provides O-&agr;-acyloxyalkyl ethers of the venlafaxine metabolite 4-[2-(Dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol, represented by Formula (I): 1Type: ApplicationFiled: November 21, 2001Publication date: March 28, 2002Applicant: American Home Products CorporationInventors: John P. Yardley, Magid A. Abou-Gharbia, John W. Ullrich
-
Publication number: 20020035158Abstract: The present invention provides enantiomers of N-Desmethyl venlafaxine, as well as their use in pharmaceutical compositions and medically useful treatments, particularly including central nervous system uses.Type: ApplicationFiled: November 20, 2001Publication date: March 21, 2002Applicant: American Home Products CorporationInventors: John P. Yardley, Andre A. Asselin
-
Publication number: 20020022662Abstract: This invention provides pharmaceutically active enantiomers of the venlafaxine metabolite O-Desmethyl venlafaxine, R(−)-4-[2-(Dimethylamnino-1-(1-hydroxycyclo-hexyl)ethyl]phenol or R(−)1-[2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclo-hexanol, and S(+)-1-[2-(Dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol or S(+)-4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol, or one or more pharmaceutically acceptable salts or salt hydrates thereof, as well as pharmaceutical compositions utilizing these enantiomers and methods of using the enantiomers to treat, inhibit or control central nervous system disorders.Type: ApplicationFiled: September 21, 2001Publication date: February 21, 2002Applicant: American Home Products CorporationInventors: John P. Yardley, Andre A. Asselin
-
Patent number: 6348494Abstract: This invention provides O-&agr;-acyloxyalkyl ethers of the venlafaxine metabolite 4-[2-(Dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol, represented by Formula (I): wherein: the configuration at the steriogenic center (*) may be R, S, or RS (the racemate); wherein radicals R1, R2, R3, R4, and R5 are as defined in the specification; as well as pharmaceutical compositions and methods treating central nervous system disorders.Type: GrantFiled: November 21, 2000Date of Patent: February 19, 2002Assignee: American Home Products CorporationInventors: John P. Yardley, Magid A. Abou-Gharbia, John W. Ullrich
-
Patent number: 5519025Abstract: This invention provides anxiolytic/antidepressant agents of the formula: ##STR1## in which R.sup.1 is alkyl;R.sup.2 and R.sup.3 are alkyl or taken together they are polymethylene;R.sup.4 is hydrogen or alkyl;R.sup.5 is phenyl, benzyl, substituted phenyl, or substituted benzyl in which the substituents are hydroxy, halo, alkoxy, trifluoromethyl, nitro, cyano, alkoxycarbonyl, amino or dialkylamino;or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 10, 1995Date of Patent: May 21, 1996Assignee: American Home Products CorporationInventors: John P. Yardley, Horace Fletcher, III
-
Patent number: 5486518Abstract: This invention provides anxiolytic/antidepressant agents of the formula:A compound of the formula: ##STR1## in which R.sup.1 is alkyl, cycloalkyl, aryl or arylalkyl;R.sup.2 is hydrogen or alkyl;R.sup.3 is phenyl, benzyl, substituted phenyl, or substituted benzyl in which the substituents are hydroxy, halo, alkoxy, trifluoromethyl, nitro, cyano, alkoxycarbonyl, amino or dialkylamino;or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 10, 1995Date of Patent: January 23, 1996Assignee: American Home Products CorporationInventors: John P. Yardley, Horace Fletcher, III, Michael G. Kelly, Alan C. White